Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) EBT Margin (2016 - 2025)

Historic EBT Margin for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to 20.27%.

  • Amicus Therapeutics' EBT Margin rose 154800.0% to 20.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.83%, marking a year-over-year increase of 146800.0%. This contributed to the annual value of 5.44% for FY2024, which is 321400.0% up from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' EBT Margin is 20.27%, which was up 154800.0% from 12.4% recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' EBT Margin registered a high of 20.27% during Q3 2025, and its lowest value of 103.48% during Q1 2022.
  • Moreover, its 5-year median value for EBT Margin was 39.48% (2024), whereas its average is 42.34%.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by -155400bps in 2022, then skyrocketed by 520400bps in 2023.
  • Over the past 5 years, Amicus Therapeutics' EBT Margin (Quarter) stood at 97.74% in 2021, then increased by 19bps to 79.55% in 2022, then surged by 65bps to 27.51% in 2023, then soared by 119bps to 5.3% in 2024, then skyrocketed by 283bps to 20.27% in 2025.
  • Its last three reported values are 20.27% in Q3 2025, 12.4% for Q2 2025, and 14.41% during Q1 2025.